|23rd October 2020||Timothy A Springer||994,488||Open or private purchase||$2.71||$2,699,736.57|
|22nd October 2020||Timothy A Springer||1,770,204||Open or private purchase||$2.63||$4,656,698.64|
|21st October 2020||Timothy A Springer||880,000||Open or private purchase||$2.50||$2,199,472.00|
|20th October 2020||Timothy A Springer||910,000||Open or private purchase||$2.21||$2,013,193.00|
|20th October 2020||Holdings A/S Novo||737,071||Conversion of derivative||$0.00|
|20th October 2020||Holdings A/S Novo||2,442,080||Conversion of derivative||$0.00|
|20th October 2020||Holdings A/S Novo||150,000||Open or private purchase||$18.00||$2,700,000.00|
|20th October 2020||Holdings A/S Novo||200,000||Open or private purchase||$15.00||$3,000,000.00|
|20th October 2020||Holdings A/S Novo||2,414,563||Conversion of derivative||$0.00|
|19th October 2020||Timothy A Springer||759,500||Open or private purchase||$2.36||$1,795,002.30|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.
Morphic Holding, Inc. engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline.